Enovis CORP (ENOV)
Enovis CORP (ENOV) from its SEC filings: 2025 revenue $2.2 billion (+7% vs the year before), net margin -53%, free cash flow $19.9 million. Insider trades, recent filings and a price chart. Free.
| Exchange | NYSE |
| Industry | Orthopedic, Prosthetic & Surgical Appliances & Supplies |
| Revenue (2025) | $2.2 billion |
| Revenue growth | +7% |
| Net income | -$1.2 billion |
| Net margin | -52.7% |
| Free cash flow | $19.9 million |
| Diluted EPS | $-20.75 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +3% |
| Cash | $12.6 million |
| Long-term debt | $1.2 billion |
| Share count, 1 year | +1% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.